Healthcare / Medical Care FacilitiesNasdaqGM
$5.30
-0.08 (-1.49%)
FCF base 3Y
$0.08
-75.1% CAGR · yield 9.3%
FCF base 5Y
$0.07
-58.0% base · -52.4% expected
Precio de entrada
$0.03
MOS 28% · confianza 44%
FCF escenarios
modelled · normalized FCF $692000.00 · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
30/100
-19.7% upside
5Y CAGR
-52.4%
0/100
Data QA
100/100
SEC 100%
Sin guardar todavía.
Market Cap
$374M
P/E
N/A
•EV/EBITDA
323.9x
↑ROE
-13.3%
↓Gross Margin
59.4%
↑Debt/Equity
0.64
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+24.3%
FCF CAGR
+5.6%
FCF margin
0.5%
FCF / Net income
-0.06x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $151.8M · net income $-11.7M · FCF $692000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $151.8M | $151.8M | $180.3M | $195.9M | $168.8M | $133.3M | $62.8M | $41.2M |
| Net Income | $-11.7M | $-11.7M | $-8.0M | $-4.2M | $-14.7M | $10.6M | $7.6M | $-2.2M |
| EBITDA | $1.2M | $1.2M | $10.3M | $20.0M | $3.5M | $22.4M | $15.7M | $5.6M |
| EPS | -0.19 | -0.19 | -0.14 | -0.08 | -0.26 | -0.01 | — | — |
| Gross Margin | 59.4% | 59.4% | 60.5% | 62.3% | 62.8% | — | — | — |
| Operating Margin | -7.6% | -7.6% | -0.9% | 5.0% | -2.7% | 11.8% | 16.0% | 1.6% |
| Net Margin | -7.7% | -7.7% | -4.4% | -2.2% | -8.7% | 7.9% | 12.1% | -5.4% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.64 | 0.64 | 0.89 | 0.87 | 1.18 | 0.99 | — | — |
| Current Ratio | 0.75 | 0.75 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $692000.00 | $692000.00 | $-2.7M | $14.0M | $11.5M | $19.5M | $10.3M | $499000.00 |
| Returns | ||||||||
| ROE | -13.3% | -13.3% | -10.3% | -5.1% | -20.7% | 12.6% | — | — |
| Valuation | ||||||||
| EV/EBITDA | 323.92 | 323.92 | 42.52 | 25.40 | 93.13 | — | — | — |
| P/B | 2.66 | 2.66 | 2.85 | 2.65 | 3.04 | 2.57 | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -15.8% | -15.8% | -7.9% | 16.1% | 26.6% | 112.4% | 52.2% | — |
| EPS Growth | -35.7% | -35.7% | -75.0% | 69.2% | -2500.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → -0.19
Residual
+20.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.